A Special Access Program for the Prophylactic Vaccination With IMVAMUNE® for Personnel Working Directly With or in the Vicinity of Replicating Vaccinia Virus

Next Previous
Trial Profile

A Special Access Program for the Prophylactic Vaccination With IMVAMUNE® for Personnel Working Directly With or in the Vicinity of Replicating Vaccinia Virus

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Smallpox vaccine (Primary)
  • Indications Monkeypox; Smallpox
  • Focus Therapeutic Use
  • Sponsors Bavarian Nordic

    • Most Recent Events

    • 22 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top